30,105 Sarepta Therapeutics, Inc. $SRPT Shares Bought by Privium Fund Management B.V.

Privium Fund Management B.V. lifted its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 22.1% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 166,605 shares of the biotechnology company’s stock after purchasing an additional 30,105 shares during the quarter. Privium Fund Management B.V. owned about 0.16% of Sarepta Therapeutics worth $3,036,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. BlackRock Inc. acquired a new position in shares of Sarepta Therapeutics in the second quarter valued at approximately $341,339,000. First Trust Advisors LP boosted its position in Sarepta Therapeutics by 107.6% in the 1st quarter. First Trust Advisors LP now owns 4,135,788 shares of the biotechnology company’s stock valued at $89,995,000 after buying an additional 2,143,211 shares during the period. Bank of America Corp DE boosted its position in Sarepta Therapeutics by 26.6% in the 1st quarter. Bank of America Corp DE now owns 2,145,926 shares of the biotechnology company’s stock valued at $46,695,000 after buying an additional 450,336 shares during the period. Renaissance Technologies LLC boosted its position in Sarepta Therapeutics by 43.6% in the 1st quarter. Renaissance Technologies LLC now owns 1,665,078 shares of the biotechnology company’s stock valued at $36,232,000 after buying an additional 505,500 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Sarepta Therapeutics in the second quarter worth $17,494,000. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Key Headlines Impacting Sarepta Therapeutics

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Royal Bank of Canada raised its price target from $17 to $18, while maintaining a “sector perform” rating. Sarepta reported Q3 EPS of $0.13, above the $0.07 consensus cited by MarketBeat, and revenue of $381.35 million versus its $352.20 million estimate. MarketBeat earnings report
• Neutral Sentiment: Baird lowered its price target to $18. The target is close to the $17.82 share price cited in the report, suggesting limited upside at that level. StreetInsider report
• Negative Sentiment: Other earnings coverage said SRPT’s $0.13 EPS missed the Zacks consensus estimate of $0.37. Revenue was down 4.5% year over year, and reports said weaker Elevidys sales weighed on investor sentiment. Published earnings benchmarks differ, so the quarter’s result depends on which estimate is used. Zacks earnings coverage
• Negative Sentiment: A Sarepta-Hansa gene-therapy study has ended, raising questions for investors about the collaboration and its development prospects. The available report summary does not specify the study’s results or implications. TipRanks report

Sarepta Therapeutics Stock Up 1.4%

Shares of NASDAQ:SRPT traded up $0.25 during trading hours on Friday, reaching $17.82. The stock had a trading volume of 2,596,194 shares, compared to its average volume of 2,726,443. Sarepta Therapeutics, Inc. has a 1 year low of $14.68 and a 1 year high of $24.68. The firm’s 50 day moving average is $19.13 and its 200-day moving average is $18.64. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.62 and a current ratio of 4.42. The stock has a market capitalization of $1.88 billion, a price-to-earnings ratio of -13.01, a P/E/G ratio of 0.33 and a beta of 0.45.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.06. The business had revenue of $381.35 million during the quarter, compared to analysts’ expectations of $352.20 million. Sarepta Therapeutics had a negative net margin of 13.48% and a negative return on equity of 1.60%. The company’s revenue for the quarter was down 4.5% on a year-over-year basis. During the same period in the previous year, the company earned ($0.13) EPS. Research analysts predict that Sarepta Therapeutics, Inc. will post 3.27 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

SRPT has been the topic of a number of recent research reports. Robert W. Baird set a $18.00 price objective on Sarepta Therapeutics in a research report on Friday. Needham & Company LLC reissued an “underperform” rating on shares of Sarepta Therapeutics in a research note on Monday, September 28th. HC Wainwright restated a “sell” rating and set a $5.00 price target on shares of Sarepta Therapeutics in a report on Monday, October 5th. Royal Bank Of Canada increased their price target on Sarepta Therapeutics from $17.00 to $18.00 and gave the company a “sector perform” rating in a research report on Friday. Finally, Benchmark reiterated a “sell” rating on shares of Sarepta Therapeutics in a research note on Wednesday, September 9th. Six research analysts have rated the stock with a Buy rating, five have given a Hold rating and seven have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus target price of $23.40.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc (NASDAQ: SRPT) is a biotechnology company focused on developing and commercializing precision genetic medicines for rare diseases. Its research programs use RNA-based technologies, gene therapy and other genetic approaches to address the underlying causes of serious neuromuscular disorders.

The company’s primary focus is Duchenne muscular dystrophy (DMD), a progressive genetic disease that causes muscle weakness and loss of function. Sarepta markets Exondys 51 (eteplirsen), Vyondys 53 (golodirsen) and Amondys 45 (casimersen), RNA-based therapies designed to help certain patients produce a shortened but functional form of dystrophin.